No profile data available.
Zenas BioPharma, Inc. (ZBIO) is a healthcare company in the autoimmune treatment pharmaceuticals industry, based in Waltham, United States, with about 167 full-time employees.
It reported revenue of $10.00 million for fiscal year 2025, up 100.0% from fiscal year 2024, and net income of -$377.74 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $1.00 million. Its market capitalization was $1.78 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Zenas BioPharma reported $10.00 million in revenue for fiscal year 2025, up 100.0% from $5.00 million in fiscal year 2024. In Q2 2026 revenue was $1.00 million.
$1.78 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (autoimmune treatment pharmaceuticals) include Aurinia Pharmaceuticals Inc. (AUPH), Viridian Therapeutics, Inc. (VRDN), Alvotech (ALVO), Alumis Inc. (ALMS).